Richard Steinhart - 07 Jan 2025 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Chief Financial Officer
Signature
/s/ Richard Steinhart
Issuer symbol
BTAI
Transactions as of
07 Jan 2025
Net transactions value
$0
Form type
4
Filing time
10 Jan 2025, 20:00:12 UTC
Previous filing
17 Dec 2024
Next filing
17 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Stock Option (right to buy) Award $0 +270,000 $0.000000 270,000 07 Jan 2025 Common Stock 270,000 $0.4713 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 7, 2025, the Reporting Person was granted an option to purchase 270,000 shares of common stock, which vests in twelve equal monthly installments over a twelve-month period following the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.